160 related articles for article (PubMed ID: 26708906)
1. [Research Progress on Co-stimulating Molecule B7-H3 in Hematological Malignancies].
Zhang W; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1758-62. PubMed ID: 26708906
[TBL] [Abstract][Full Text] [Related]
2. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
3. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
5. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
[TBL] [Abstract][Full Text] [Related]
6. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.
Hashiguchi M; Kobori H; Ritprajak P; Kamimura Y; Kozono H; Azuma M
Proc Natl Acad Sci U S A; 2008 Jul; 105(30):10495-500. PubMed ID: 18650384
[TBL] [Abstract][Full Text] [Related]
7. B7-H3 targeted antibody-based immunotherapy of malignant diseases.
Michelakos T; Kontos F; Barakat O; Maggs L; Schwab JH; Ferrone CR; Ferrone S
Expert Opin Biol Ther; 2021 May; 21(5):587-602. PubMed ID: 33301369
[No Abstract] [Full Text] [Related]
8. Murine b7-h3 is a co-stimulatory molecule for T cell activation.
Yan R; Yang S; Gu A; Zhan F; He C; Qin C; Zhang X; Feng P
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):395-8. PubMed ID: 24328742
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
10. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
11. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of costimulatory molecule B7-H3 expression on CD3(+) T cells in colorectal carcinoma.
Mao Y; Sun J; Wang WP; Zhang XG; Hua D
Chin Med J (Engl); 2013 Aug; 126(16):3035-8. PubMed ID: 23981607
[TBL] [Abstract][Full Text] [Related]
13. B7-H3: A promising therapeutic target for autoimmune diseases.
Chen Y; Guan SY; Deng J; Yang H; Xu W; Xu S; Shao M; Gao X; Xu S; Shuai Z; Pan F
Cell Immunol; 2020 Jun; 352():104077. PubMed ID: 32113615
[TBL] [Abstract][Full Text] [Related]
14. The B7 homologues and their receptors in hematologic malignancies.
Wilcox RA; Ansell SM; Lim MS; Zou W; Chen L
Eur J Haematol; 2012 Jun; 88(6):465-75. PubMed ID: 22372959
[TBL] [Abstract][Full Text] [Related]
15. B7-H3 in Cancer - Beyond Immune Regulation.
Flem-Karlsen K; Fodstad Ø; Tan M; Nunes-Xavier CE
Trends Cancer; 2018 Jun; 4(6):401-404. PubMed ID: 29860983
[TBL] [Abstract][Full Text] [Related]
16. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma.
Sun J; Chen LJ; Zhang GB; Jiang JT; Zhu M; Tan Y; Wang HT; Lu BF; Zhang XG
Cancer Immunol Immunother; 2010 Aug; 59(8):1163-71. PubMed ID: 20333377
[TBL] [Abstract][Full Text] [Related]
18. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
19. Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.
Calabrò L; Sigalotti L; Fonsatti E; Bertocci E; Di Giacomo AM; Danielli R; Cutaia O; Colizzi F; Covre A; Mutti L; Natali PG; Maio M
J Cell Physiol; 2011 Oct; 226(10):2595-600. PubMed ID: 21792917
[TBL] [Abstract][Full Text] [Related]
20. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
